Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

03 December 2020

Visiongain has published a new report on Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031: Forecasts by Vector Types (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), End-use (Pharma and Biopharma Companies, Research Institutes), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). PLUS Analysis of Leading Viral Vectors & Plasmid DNA Manufacturing Companies AND COVID-19 Recovery Scenarios.

Global Viral Vectors and Plasmid DNA Manufacturing market size is projected to be valued at US$ xx billion in 2020 and is further expected to reach US$ xx billion in 2026 while growing at a CAGR of xx% during the first half of the forecast period i.e. 2021 to 2026. The global market size is further projected to reach US$ xx billion by 2031 at a CAGR of xx% from 2026 to 2031. The overall CAGR for the global Viral Vectors and Plasmid DNA Manufacturing market is expected to be xx% from 2021 to 2031.

COVID-19 Impact on Viral Vectors and Plasmid DNA Manufacturing Market
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19. The number of companies developing innovative medicines such as cell, gene, & tissue-based therapies surpassed 1,000 in the first half of 2020, according to the ARM (Alliance for Regenerative Medicine). Since 2015, that represents an upsurge of almost 50%. Increases in clinical trial activity have corresponded to the emergence of successful advanced therapy companies.

Market Drivers

Robust Pipeline for Gene Therapy and Viral Vectors
Almost 400 Embryonic cell and gene therapies address a broad variety of diseases. The overlapping areas of biomedical science with common therapeutic targets that target DNA or RNA within or outside the body are cell and gene therapy. To optimize functioning or tackle the disease, all techniques aim to alter genetic material. Specifically, gene therapy uses genetic material, or DNA, to cure an inherited or acquired disorder by modifying a patient's cells. The injection or transplantation of whole cells into a recipient for the treatment of an inherited or acquired disorder is cell therapy.

Increasing Capacities by Manufacturers Owing to Rising Demand
There is a growing need for realistic production methods for viral vectors that can be quickly standardized and scaled since cell and gene therapies have the ability to progress rapidly from clinical trials through commercialization. Brammer Bio and Pall Biotech are both designing and applying state-of-the-art solutions designed to speed up process growth and scale-up for the manufacture of viral vectors through ongoing efforts. While biological drug substances with lower molecular weight are often generated through fermentation, larger recombinant proteins and monoclonal antibodies (mAbs) are usually manufactured using well-established platform processes, accounting for the largest fraction of biologics on the market today. As a consequence, manufacturing equipment has been built for the production of mAbs, and this room is well serviced by suppliers of equipment.

Market Opportunities

The rise in the Development of Allogeneic and Autologous Cell Therapy
The more commercially appealing development of allogeneic cell therapy currently dominates over the production of autologous cell therapy, while clinical research in support of patient-specific therapy is convincing. There are opportunities for both autologous and allogeneic cell therapies to be developed, which differ greatly in their production requirements, patient administration paths, and cost structures.

In an autologous transplant, the patient's own stem cells are used for transplantation purposes for the treatment of many diseases such as cancer. The stem cells are obtained from either bone marrow or blood and are then frozen for harvest purposes. High doses of chemo or radiation therapy damage different cells of the body. Thus, after these therapies during cancer treatment, the thawed stem cells are reintroduced into the patient's body to restore the damaged cells. As the patient's own cells are used during autologous stem cell transplantation, there would be no risk of transplant rejection. This type of transplant is mainly utilized for the treatment of types of leukemia, lymphomas, and multiple myeloma. It is occasionally used to treat cancers in children and follicular lymphoma.

Competitive Landscape
Some of the major companies operating in the global Viral Vectors and Plasmid DNA Manufacturing market are Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Brammer Bio, Waisman Biomanufacturing, Genezen, YPOSKESI, Advanced BioScience Laboratories, Inc. (ABL, Inc.), Novasep Holding S.A.S, ATVIO Biotech Ltd, Vigene Biosciences, Inc., Cytiva, CEVEC Pharmaceuticals GmbH, Batavia Biosciences B.V, Biovian Oy, Wuxi AppTec Co., Ltd., VGXI, Inc., Paragon Bioservices, Inc., Miltenyi Biotec GmbH, SIRION Biotech GmbH, Virovek Incorporation, BioNTech IMFS GmbH, VIVEbiotech S.L., Creative Biogene, Vibalogics GmbH, Cell and Gene Therapy Catapult, BlueBird Bio, Addgene, Inc., Aldevron, L.L.C., Audentes Therapeutics, and BioMarin Pharmaceutical.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022


Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022


Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022


Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022